A B S T R A C T The metabolic clearance rate (MCR) and renal clearance rate (RCR) of human chorionic gonadotropin (hCG) were measured in healthy young men and women using techniques of continuous intravenous infusion and rapid intravenous injection of unlabeled, highly purified hCG. Seven subjects received 4 d of infusion at a rate of 0.2 ,ug/min, followed by an additional 4 d of infusion at 0.8 ,ug/min. Mean serum levels of hCG established at these rates of infusion were 61.1±3.3 and 237±16 ng/ml, respectively (mean ±SEM). The MCR determined at the low infusion rate was not significantly different from that determined at the higher infusion rate (1.83±0.09 vs. 1.95±0.14 ml/min per m2). The mean MCR for all subjects was 1.88±0.08 ml/min per M2. The MCR was not significantly different between men and women (2.04 ±0.13 vs. 1.76±0.07 ml/min per m2). The RCR also did not vary between low and high infusion rates (0.40±0.03 vs. 0.40±0.04 ml/min per m2). The mean RCR for all subjects was 0.40±0.02 ml/min per M2. There was no difference in RCR between men and women (0.42 ± 0.05 vs. 0.39±0.03 ml/min per m2). Six subjects were given 1.0 mg of highly purified hCG by rapid intravenous injection. Initial serum levels ofhCG were 300-400 ng/ml, and the subsequent disappearance curve was multiexponential over 8-10 d. The disappearance curve of hCG in each subject was fitted to a biexponential equation. The rapid component tl2 was 5.97±0.63 h and the slow component t1/2 was 35.6±8.0 h. We conclude that the MCR of purified hCG in man is about 2 ml/min per m2 and the RCR is 0.4 ml/min per M2; these parameters are concentration independent and do not
INTRODUCTION
The metabolism of human chorionic gonadotropin (hCG)1 has been the subject of a number of reports during the past 40 yr (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . It has been established that the hCG molecule has a plasma metabolic clearance rate (MCR) that is quite slow relative to the MCR of the pituitary glycoprotein hormones (1) (2) (3) (4) (5) , and that urinary excretion accounts for some, but not all, of the metabolic disposal of hCG (1, 2, (5) (6) (7) (8) (9) (10) . Techniques for quantitation of hCG metabolism have varied, and each has its limitations. For example, the disappearance of endogenous hCG after delivery of the placenta has been determined by radioimmunoassay (1, 4) ; however, a number of hCG-related molecules circulate during pregnancy and gestational trophoblastic disease (11) (12) (13) (14) (15) , and these species may have differing rates ofdisappearance. Furthermore, the persistence ofhCG secretion by some residual trophoblastic tissue may complicate the kinetic analysis. Some investigators have injected crude commercial preparations of hCG and have analyzed the kinetics of disappearance of hCG biological or immunological activity from blood (2, 3, 5) . However, crude preparations of hCG contain immunologically active, but biologically inactive hCG-related peptides (5) . Accordingly, we have used highly purified hCG to study the metabolism of hCG. Our experimental approach was to use both a single injection technique, as employed by other investigators, and a continuous intravenous infusion, the latter technique not having been applied to the measurement of hCG metabolic parameters heretofore.
METHODS Materials
We obtained the highly purified hCG CR121 preparation from the Center for Population Research of the National Institute of Child Health and Human Development. It was prepared by Dr. Robert Canfield and Dr. Steven Birken using the same method as used for hCG CR119 (16) . We have found these two hCG preparations to be indistinguishable by a variety of criteria, including potency in bioassay, radioimmunoassay, and LH-CG radioreceptor assay systems, and gel filtration pattern on Sephadex G-100. The biological potency of hCG CR121 is 14,000 IU/mg (9,900-17,300 IU/mg, 95% confidence limits) in terms ofthe Second International Standard of hCG (ventral prostate weight bioassay). The hCG CR121 preparation was made suitable for human administration by millipore filtration. The antisera to hCG,8 (SB6) and to hCGa (SA7) have been characterized previously (13, 17) . Antiserum generated against the carboxy-terminal peptide of hCG,8 was also employed (18) . Concanavalin A covalently bound to Sepharose 4B (Con A-Sepharose) was purchased from Pharmacia Fine Chemicals, Piscataway, N. J. a-Methyl-D-mannoside was purchased from Sigma Chemical Co., St. Louis, Mo.
Subjects
Six male and seven female National Institutes of Health Clinical Center nornal volunteers, aged 18-22 yr, participated in the study after giving informed consent. Injections or infusions of hCG were given to the women late in the luteal phase or during menstruation to avoid the ovulatory surge of luteinizing hormone.
Base-line samples
Three base-line 24-h urine specimens and three base-line blood samples (10 ml) were obtained from each subject before the administration of hCG.
Continuous infusion technique
Seven subjects (three men and four women) were given purified hCG by continuous intravenous infusion. The subjects were allowed to pursue their normal diets and activities within the constraints imposed by the intravenous infusion apparatus (IMED portable intravenous flow pump). At 0800 h of the 1st d, a loading dose of 0.2 mg of purified hCG was injected intravenously, and continuous infusion was begun of a solution of 500 ml 0.9% NaCl containing 0.15 mg hCG and 2 ml of 25% human serum albumin. The infusion was maintained at a flow rate of40 ml/h. The intravenous solutions were prepared fresh and changed every 12 h. After 4 d (96 h), an additional 0.6 mg of purified hCG was injected intravenously, and the concentration of hCG in the infusate was increased to 0.6 mg/500 ml. The actual flow rate was determnined on several occasions by measuring the weight of fluid delivered during 12 h by the pump into a tared collection flask. The mean flow rate determined in this way was 38.9±0.7 ml/h (±SD). An aliquot of the infusate given to each subject was stored at -20°C until assayed for hCG; thus, it was possible to measure the rate ofinfusion ofhCG during each 12-h period. Blood samples (10 ml) were drawn from the contralateral arm every 12 h, just before the intravenous solution was changed. 24-h urine specimens were obtained each day during the 8-d infusion period. Because of technical difficulties with maintaining the intravenous infusion, data were not obtained in two subjects at the higher rate of infusion.
Single injection technique
At 0800 h, after overnight fasting, six subjects (three men and three women) were given a rapid intravenous injection of 1.0 mg of purified hCG in 5 ml of 0.9% NaCl into a right antecubital vein. Blood samples (10 ml) were obtained at various times during the next 16 h via an intravenous line in a left forearm vein; the line was kept open by an infusion of 0.9% NaCl at 40 ml/h. During the day of injection, the subjects were allowed a clear liquid lunch. After 8 h at bed rest, normal diet and activities were resumed. Additional blood samples (10 ml) were taken daily for the next 8-12 d, and 24 h urine specimens were collected for each of 12-15 d after injection. Creatinine concentration was measured in each urine specimen to ensure that adequate collections had been obtained.
Processing of sam ples
All samples of blood were allowed to clot and were centrifuged at 1500 g for 15 min to separate the serum. Urine was kept refrigerated until the end of the collection period. Aliquots of serum, urine, and infusate were stored at -20°C for subsequent analysis.
Radioimmunoassays
The hCG,3 determinant radioimmunoassay employed antiserum generated against the hCG,/ subunit (SB6) (17) ; hCG CR119 iodinated with 125I by the chloramine T method (19) was used as the radioligand, and hCG CR121 was the reference preparation.
The hCGa determinant radioimmunoassay used antiserum against the hCGa subunit (SA7) (13) ; hCGCa (CR119), iodinated with 1251 by the chloramine T method (19) , was used as the radioligand, and hCGa (CR119) was the reference preparation.
The hCG,8 carboxy-terminal peptide determinant radioimmunoassay used an antiserum to the hCGJ3 carboxyterminal peptide (18) in a system which used labeled hCG CR119 as the radioligand and hCG CR121 as the reference preparation.
Serum and infusate samples
To eliminate interassay variability, serum and infusate samples from individual subjects were run in the same assay. Aliquots of infusate and sera derived from the continuous infusion techniquie were diluted in radioimmuinoassay buffer, and potency estimates were made using the reference preparation diluted in the same buffer. Each unknown sample was run in the assay at three different dilutions, such that the resulting displacement of radioligand was between 20 and 80% in at least two of the three dilutions. Dose interpolations for the unknown samples were made using parallel line bioassay statistical methods (20) .
For subjects given hCG by rapid injection, sera and standards were diluted in normal male (blank) serum to a volume of 200 ,LI.
Urine samples
To minimize nonspecific effects of urine on the radioimmunoassays, Con A-Sepharose was used to extract hCG from the urine specimens as described previously (21, 22) . Briefly, amounts of urine up to 1.5 ml were mixed with 300 ,ul of a slurry of Con A-Sepharose (1:1, vol/vol in phosphate-buffered saline [PBS, 0.15 M NaCl, 0.01 M P04, pH 7.4]) and mixed by vortex three to four times during 45 min at room temperature. Recovery of the purified hCG by this procedure was 92+5% and was accounted for in calculating the results. a-Methyl-D-mannoside (0.25 M final concentration) was added to the routine radioimmunoassay buffer to inhibit adsorption of labeled hCG to the Con A-Sepharose gel.
Gel filtration
Samples of urine and infusate (1.0 ml), with 5-10,000 cpm of 125I-hCGa added as a column marker, were applied to a column of Sephadex G-100 (69.5 x 1.6 cm) and eluted with PBS by upward filtration at a flow rate of 25 ml/h. Fractions of 2.3 ml were collected and an aliquot of each fraction was counted for l25I.
Samples of serum (2.0 ml), with 5-10,000 cpm of 125I-hCGa added as a column marker, were applied to a column of Sephadex G-100 (83.5 x 2.6 cm), and eluted with PBS by upward filtration at 25 ml/h. Fractions of 2.3 ml were collected and aliquots counted for 125I. The fractions obtained from these columns were assayed in the various radioimmunoassays either directly or after Con A-Sepharose extraction. The immunoreactive moieties which eluted from the column contained sufficient carbohydrate for adsorption to Con A-Sepharose.
Analysis of data
Continuous infusion. The steady-state serum concentration of hCG during the infusion was used to calculate the MCR by the formula, MCR = IR/C, where IR is the infusion rate (ng/min) and C is the steady-state serum concentration (ng/ml). The renal clearance rate (RCR) was calculated according to the formula, RCR = U/C, where U is the quantity of hCG excreted in the urine during the period, and C is the steady-state serum concentration.
Single injection. The disappearance of hCG from serum was curvilinear on a semilog plot, and for purposes of calculating curve parameters and estimating clearance rates from the data, a curve-fitting computer program (23) The RCR was calculated as the amount of hCG excreted in the urine during the first 72 h after injection divided by the integral of the disappearance curve during this same time period. The formula used was RCR = U/(f3 Cdt), where U is the quantity of hCG excreted in the urine during the 72 h, C is the serum concentration, and t is the time.
Body surface area was estimated from height and weight by the formula of Du Bois and Du Bois (24) .
Statistical analysis of the radioimmunoassays was performed as described by Rodbard (20) . For comparison of means, we used Student's t test (25) .
RESULTS
MCR of hCG determined by continuous infusion technique. Base-line serum levels of hCG were at or below the limits of detection of the radioimmunoassay (:s 1.0 ng/ml) in all subjects. An initial rapid intravenous injection of hCG was given to raise rapidly the blood level to near the desired concentration. Fig. 1 shows the levels of hCG which were achieved in the serum of the subjects during the infusion ofhCG at 0.2 ,g/min and 0.8 ,g/min. Mean serum hCG levels on the 3rd d of continuous infusion were not significantly different from those on the 4th d (paired t test, 0.05 level). For each subject, the serum hCG levels during the 3rd and 4th d were averaged, and the average value was used to calculate the MCR and RCR. For the seven subjects, the mean serum hCG levels during the final 48 h of the low and the high infusion rates were 61.1+3.3 and 237±16 ng/ml (mean± SEM), respectively. The MCR of hCG was 1.88±0.08 ml/min per m2 (Table I) , and there was no significant difference between the men and the women (2.04+0.13 vs. 1.76±0.07 ml/min per m2). The MCR of hCG at the low infusion rate did not differ significantly from that at the high infusion rate (Table I) . RCR of hCG determined by the continuous infusion technique. For the seven subjects, the mean daily hCG excretion rates during days 3 and 4 of infusion were 58.6 and 233.9 ,g/24 h for the low and high infusion rates, respectively (Table II) . The percent of administered hCG excreted in urine varied among the subjects from 17 to 28% (21.6+1.1, mean ±SEM). The RCR of hCG determined in each subject was similar at the high and low infusion rates. The mean value for the RCR was 0.40±0.02 ml/min per M2. There was no significant difference in RCR between men and women (0.42±0.05 vs. 0.39±0.03 ml/min per m2).
Characterization of serum and urine hCG immunoreactivity. Accumulation of hCG subunits or of immunoreactive metabolites in the serum or urine during the infusion could influence the accuracy of the hCG levels determined, and hence the MCR and RCR calculated from these values. Accordingly, we examined the nature of the immunoreactive hCG in serum and urine in order to ascertain the extent to which the total hCG immunoreactivity consisted of crossreactivity from hCG subunits or metabolites.
After Sephadex G-100 gel filtration of the base-line (Fig. 2) . The larger apparent molecular size form of hCG immunoreactivity was not apparent in chromatographs of the hCG preparation incubated with or without the subjects' sera. It may (Fig. 2) . Gel filtration of the urine obtained on the 8th d of the hCG infusion revealed that the vast majority of the hCG,8 immunoreactivity eluted in fractions corresponding to intact hCG (Fig. 3, upper panel) . There was no apparent free hCG/3 subunit of a size similar to that of authentic hCG,8 in any of the subjects.
However, the urine of the subject illustrated here did contain a small amount of hCG,8 immunoreactivity which eluted from the column with a larger exclusion volume than hCG, hCGa, or hCG,3. This substance with hCGJ3 immunoreactivity had a Kay on this column, which was essentially identical with that of the discrete degradation product of the hCG,8 subunit that we have described previously (26) . However, this small molecular size form of hCG8 immunoreactivity constituted a minute portion of the total hCG,B immunoreactivity eluted from the column and was not detected in the eluate obtained from gel filtration of the urine of the other six subjects. Hence, with the infusion of purified hCG, the overwhelming majority of the hCGP immunoreactivity excreted in urine was hCG itself.
When base-line urine was gel filtered, minor amounts of hCGa immunoreactivity were observed in the position corresponding to that of free hCGa (Fig. 3 , lower panel) confirming our previous experience (22 appreciably (Fig. 3) . Thus, there is no evidence for degradation of hCG to an hCGa-like material, similar to that which has been reported to exist in pregnancy serum and urine (11, 12, 14) .
The hCG,C carboxy-terminal peptide radioimmunoassay was used to obtain another estimate of the quantity and immunological character of the hCG in the serum and urine specimens obtained during the continuous infusion of purified hCG. We reasoned that if the infused hCG were unaltered, and if negligible quantities of immunoreactive metabolites had accumulated, the ratio of the carboxy-terminal peptide immunological determinant level to the conformational (SB6) determinant level should be unity, i.e., equal to that in the purified hCG. The levels of these two determinants were indeed nearly identical in serum (Fig. 4 ) and in urine (Fig. 5) The slopes of the dose-response curves of the serum and urine specimens collected during infusion of hCG were not significantly different from that of authentic hCG in the hCG radioimmunoassay. The immunoreactive hCG material in both serum and urine adsorbed quantitatively to Con A-Sepharose, indicating that no deglycosylated hCG had accumulated.
In summary, when purified hCG was administered to normal subjects by continuous infusion to achieve steady state levels, the vast majority ofthe accumulated immunoreactive material detected in serum and urine by our radioimmunoassays was apparently intact hCG. Parenthetically, there may be other peptide fragments present which lacked cross-reactivity in these radioimmunoassays.
Levels of hCG in serum after single injection of hCG. Base-line serum hCG levels (hCG,B determinant radioimmunoassay) were at or below the detection limit of the assay (.1.0 nglml). After rapid intravenous injection of 1.0 mg of purified hCG the initial serum levels of hCG achieved were 300-400 nglml. Fig. 6 shows the mean hCG levels of six subjects during 7 d after injection. The serum disappearance curve is curvilinear on a semilog plot. The kinetic parameters of the computer-derived biexponential curves for each subject are given in Table III . The initial volume of distribution, when corrected for body size, was the same for men and women, and was similar to plasma volume. The rapid component t1/2 was -6 h, and the slow component t12 was -36 h. MCR and RCR of hCG determined by the single injection technique. The parameters of the serum disappearance curve of hCG were used to calculate the MCR of hCG after single intravenous injection of purified hCG in each subject. The mean MCR calculated for the group was 1.61±0.09 ml/min per m2 (Table IV) . The urinary excretion of hCG was great- FIGURE 6 Disappearance ofhCG from serum after injection ofhighly purified hCG (1.0 mg) in six normal subjects. Blood specimens were obtained at various times after rapid intravenous injection of hCG, and serum levels of hCG were measured by radioimmunoassay. Closed circles represent the mean serum hCG levels, expressed as a percentage ofthe administered dose per milliliter; the vertical lines indicate the SEM. The insert provides more detail of the disappearance during the first 12 h after injection. Table IV , the RCR of hCG in these subjects was 0.49+0.05 ml/min per M2.
DISCUSSION
Using purified hCG and a continuous infusion technique, we have determined that the MCR of hCG is -2 ml/min per m2, and that the MCR is independent ofthe serum hCG level over the range of60-240 ng/ml. The MCR, expressed in terms of body surface area, does not differ significantly between healthy young men and women. Similarly, the RCR of hCG, -0.40 ml/min per m2, is independent of the serum hCG level, and is the same for men and women. Renal excretion accounts for only 20% of the total disposal of purified hCG. The pathways for the other 80% of the disposal remain unaccounted for, but presumably involve uptake and degradation by hepatic and renal tissue (27) ; in addition, although it is clear that binding to gonadal receptors accounts for some of the metabolism of hCG (27) , this pathway is likely to be of minor quantitative significance. We gave purified hCG by continuous infusion, and our value for the MCR of hCG is 3.31+0.23 ml/min (or 1.88+0.08 ml/min per m2). In contrast, previous studies ofhCG metabolism employed analysis ofits disappearance after a single injection of crude preparations ofhCG (2, 3, 5) , or after removal ofhCG-producing tissue, e.g., delivery of the placenta (1, 4) . For example, Wide et al. (2) calculated an MCR based on bioassay measurement of hCG of 2.33 ml/min; when a radioimmunoassay was used to measure hCG, these authors found a substantially different value of the MCR, [6] [7] [8] [9] [10] h; however, the latest time point at which the hCG level was determined was 24 h in two subjects and 5 h in the third. Our value for the RCR of hCG is 0.70±+0.04 ml/min (or 0.40±0.02 ml/min/m2). Wide et al. (2) reported that the RCR was 0.70 ml/min when hCG is measured by radioimmunoassay, and 0.36 ml/min when hCG is measured by bioassay in male rats. Gastineau et al. (8) , using a rat ovarian hyperemia bioassay to measure serum and urinary hCG, found a value of 0.38 ml/min during normal pregnancy; using a rat prostate weight bioassay, Loraine (6) reported RCR values during pregnancy of 0.95±0.17 ml/min (SD). Midgley and Jaffe (1) found RCR values by radioimmunoassay which ranged from 0.59 to 1.75 ml/min after normal pregnancy and delivery; Johnson et al. (7) Despite possessing structures which are basically similar to that of hCG, the pituitary glycoprotein hormones have MCR which are considerably greater than that of hCG (29) (30) (31) (33) (34) (35) . The differences in MCR among these hormones are not necessarily attributable solely to their differences in carbohydrate composition. For exai-mple, the MCR of human luteinizing hormone (hLH) is much greater than that of hCG, but about the same as that of hCG,3 (28) (29) (30) (31) 33 ). Yet, both hCG and hCG,c are much richer in sialic acid and other carbohydrate residues than hLH. The amino acid sequence of the hLH,B subunit exhibits -80% homology with hCG,8, but hLH,8 lacks the 30 amino acid sequence at its carboxy-terminus, which is characteristic of hCG,8 (32) . Further study is necessary to clarify how these various differences in structure account for the mutch lower MCR of the hCG molecule in comparison to hLH and the other pituitary glycoprotein hormones.
